The drug in question is edivoxetine (a highly selective noradrenaline reuptake inhibitor). It reached phase III development where it failed to show significance in comparison to placebo. There appears to be no preclinical data for this drug at all.
You need approval for any Investigational New Drug (IND) before proceeding to clinical trials. Requirements for getting such approvals includes study reports on early pre-clinical trials. There is however no legal obligations to make such study report public at that point in time.